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Background: The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with
rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by mTORC2
inhibition. A first-in-human trial evaluating tolerability, pharmacokinetics and pharmacodynamics of the dual TORC1/TORC2
inhibitor OSI-027 was conducted.
Methods: Dose escalation was pursued for three schedules of administration (three consecutive days per week (S1), once a week
(S2) and daily dosing (S3)), until dose-limiting toxicities (DLT) were identified. Expansion cohorts with paired tumour biopsies were
initiated based on tolerability and pharmacodynamics.
Results: One hundred and twenty eight patients with advanced cancer were enrolled. DLT consisted predominantly of fatigue,
renal function disturbances and cardiac events. OSI-027 exposure was dose proportional, with Tmax within 4 h and a half-life of
B14 h. Expansion cohorts were initiated for S1 and S2, as MTD for S3 was overall considered suboptimal. Target modulation in
peripheral blood mononuclear cells were observed from 30mg, but in tumour biopsies 120mg QD were needed, which was a
non-tolerable dose due to renal toxicity. No RECIST responses were recorded, with stable disease46 months in six (5%) patients.
Conclusions: OSI-027 inhibits mTORC1/2 in patients with advanced tumour s in a dose-dependent manner but doses above the
tolerable levels in S1 and S3 are required for a sustained biological effect in tumour biopsies.
The mammalian target of rapamycin (mTOR) is a well-established
target for cancer therapy. mTOR is a 289-KDa serine-threonine
kinase that forms part of at least two distinct multiprotein
complexes, mTORC1 and mTORC2, both of which regulate
distinct branches of the mTOR signalling network (Sabatini, 2006).
Altogether, the mTOR complexes are key elements in cell growth,
proliferation and survival regulation. Targeting mTOR has
demonstrated anti tumour activity in clinical studies; as a result,
allosteric inhibitors of mTOR, have been approved for the
treatment of renal cell carcinoma, pancreatic neuroendocrine
tumours and advanced hormone receptor positive, HER2-negative
breast cancer (Hudes et al, 2007; Motzer et al, 2008; Yao et al, 2011;
Baselga et al, 2012).
Despite the benefit shown in some cancer types, blockade of
mTORC1 is not sufficient to completely abrogate signalling of the
PI3K/AKT/mTOR pathway (Feldman et al, 2009). Indeed, there is
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evidence that inhibition of mTORC1 by rapalogues results in the
release of a negative-feedback loop between S6K and IRS1, leading
to phosphorylation of AKT at Thr308 and Ser473, which could be
avoided by mTORC2 blockade (Cloughesy et al, 2008; Tabernero
et al, 2008).
Dual mTOR kinase inhibitors are being developed to maximise
the pharmacological impact of mTOR blockade, as mTORC2 is
insensitive to rapalogues (Jacinto et al, 2004; Becker et al, 2014;
Wilson-Edell et al, 2014). OSI-027 (also known as ASP7486)
is an orally available small molecule dual mTORC1/mTORC2
ATP-competitive kinase inhibitor, with an IC50 of 22 nM and
65 nM for mTORC1 and mTORC2, respectively. In preclinical
studies, OSI-027 demonstrated activity in a broad panel of tumour
cell lines, with IC50 valueso10 mM, including models resistant to
rapalogues. In addition, anti tumour activity was documented in
tumour xenograft models. (Bhagwat et al, 2011; Falcon et al, 2011)
Preclinical toxicology studies identified signs of immunosuppres-
sion, renal function impairment, glucose metabolism abnormalities
as well as potential for cardiac and ocular toxicities at high doses.
The maximum tolerated dose (MTD) in toxicology studies was
20mg kg 1 per day in rodents and 2.5mg kg 1 per day in
monkeys.
We present here a first-in-man study of the mTORC1/
mTORC2-targeting agent OSI-027 in patients with advanced solid
malignancies, with the primary objectives of determining a MTD
and recommend a dose for phase 2 trials. To optimise tolerability
and drug exposure, three schedules of administration were selected
for clinical investigation based on the preclinical data.
MATERIALS AND METHODS
Eligibility criteria. Patients with advanced solid tumours refrac-
tory to standard therapies were enrolled after providing written
informed consent and based on meeting eligibility criteria,
including: age X18 years, ECOG-Performance Status 0–2, fasting
glucosep7mmol l 1 and left ventricular ejection fraction (LVEF)
X60%, by multigated acquisition scan and/or echocardiography;
complete eligibility criteria are available in Supplementary
Material.
Trial design overview. Three different schedules of administra-
tion were investigated during the dose-escalation phase: once daily
for three consecutive days every week (Schedule 1 (S1)), once
weekly (Schedule 2 (S2)) and continuous once daily (Schedule 3
(S3)). The primary objective of the study was to determine MTD
and recommend a dose and schedule of OSI-027 for phase 2 trials.
Secondary objectives included tolerability, safety and pharmacoki-
netics profile, assessment of pharmacodynamics and preliminary
antitumour activity.
Dose escalation was pursued independently for each schedule
following a 3þ 3 design. Escalation was permitted if o33%
patients on a dose level experienced dose-limiting toxicities (DLT),
defined as any non-haematological adverse event grade X3 (NCI-
CTCAE v3) related with the study drug occurring during the first
cycle of treatment (21 days), with the exception of non-adequately
managed fatigue, nausea, vomiting and/or diarrhoea. In addition,
absolute reduction X15% on LVEF was also considered DLT.
MTD was defined as the immediately lower dose level to the one
where X33% of patients experienced DLT.
Expansion cohorts were planned to provide evidence of
pharmacodynamics in tumour tissue as well as to complement
the safety data. Dose for expansion cohorts was selected based on
MTD determination and the PD data in peripheral blood
mononuclear cells (PBMC).
The study was approved by the institutional review boards of all
participating centres, and sponsored by Astellas Pharma Global
Development (Northbrook, IL, USA), ClinicalTrials.gov Identifier
NCT00698243.
Treatment administered and starting dose. The investigational
product was presented in hard gelatine capsules containing 5 or
20mg of OSI-027 plus microcrystalline cellulose, hydroxypropyl
cellulose, croscarmellose sodium, and magnesium stearate as
excipients. The starting dose of 10mg QD three days per week
for S1 was selected based on preclinical toxicology studies: 9 mg
QD was the equivalent dose for human to 1/6 of the highest non-
severely toxic dose in 28-day repeated-dose studies in monkeys.
The starting dose for S2 (10mg QWK) and S3 (5mg QD) were
selected based on preliminary safety data from S1.
Study procedures
Safety assessments. Adverse events and concomitant medications
were recorded throughout the trial participation.
Guidelines for dose modifications were implemented; drug
administration was halted and/or dose was reduced for creatinine
increase grade X2 and/or if absolute values of LVEF fell X15%
from baseline. Permanent treatment discontinuation was man-
dated for LVEF drops X20%.
Pharmacokinetic assessments. Blood and urine samples were
collected at prespecified time points for 24 h after initial dose
and at days 2–3 (S2) and after multiple doses on days 3–4 (S1)
and 22–23 (S3) across dose levels. Predose samples were
collected on days 8, 15 and 22. Urine samples were collected
during cycle 1.
Pharmacodynamics studies. Drug-mediated inhibition of the
mTORC1 and mTORC2 signalling was evaluated through asses-
sing modulation of phospho-4EBP1 and phospho-PRAS40 in
PBMC, as well as phospho-4EBP1 and phospho-S6 in tumour
biopsies. Blood aliquots were collected prior to start dosing and at
prespecified time points during the first course of treatment. Fresh
tumour biopsies were obtained from selected patients during the
dose escalation stage and from all patients in the expansion
cohorts, at baseline and during cycle 1.
Antitumour activity. Assessments by imaging techniques (CT
and/or MRI) were performed every 8–12 weeks or earlier if
clinically indicated.
Statistical considerations. Descriptive statistics were used to
summarise the safety data, including all patients who received
at least one dose of OSI-027. All patients who completed the
pharmacokinetic sampling were included in the PK analyses,
which used descriptive statistics to summarise AUC0–N,
AUC0–t, Cmax, Clast, Tmax, Tlast, %AUC extrapolated, T1/2,
clearance (Cl/F) and volume of distribution (Vz/F). Exploratory
analysis were planned to correlate pharmacodynamics and
pharmacokinetics. Response to treatment was evaluated accord-
ing to Response Evaluation Criteria in Solid Tumors (RECIST)
(Therasse et al, 2000).
RESULTS
Patient characteristics. Overall, 128 patients were enrolled
in this study between July 2008 and August 2012, with 123
receiving treatment with OSI-027 (56 subjects on S1, 39 on S2
and 28 on S3). The most common primary tumour types among
the participants were colorectal (32, 25%), melanoma (13, 10.1%)
and renal (11, 8.6%) cancers. The median age of the trial
population was 56.5 years; baseline characteristics are presented
in Table 1.
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Adverse events and MTD
Dose escalation and MTD. Eleven events occurring in 11 patients
were judged as dose-limiting toxicities (DLT): grade 3 fatigue
(n¼ 4 events), grade X2 creatinine rise (2), grade 2 decreased
LVEF (1), grade 3 cardiomyopathy (1), grade 3 bone pain (1),
grade 3 maculo-papular rash (1) and grade 3 hyperglycaemia (1))
(Figure 1 and Supplementary Table 1).
In schedule 1, nine dose levels (10–160mg) were explored; one
out of six patients treated at the lower dose level (10mg)
experienced a DLT of congestive cardiac failure. At a dose of
90mg, two out of eight patients had DLT of grade 3 fatigue and
grade 3 bone pain. Dose levels of 120mg and 160mg were
explored; one event of grade 3 hyperglycaemia was identified as
DLT at 160mg. After assessment of the overall toxicity data in the
escalation phase of S1, 120mg was selected as the highest
potentially feasible dose and two expansion cohorts were opened,
for further evaluation of 90 and 120mg.
Seven dose levels from 10 to 240mg QWK were tested in
schedule 2. Dose escalation was discontinued before a formal MTD
was reached based on the large number of tablets needed. Fifteen
additional patients were treated with 240mg QWK in an expansion
cohort.
At 50mg QD (S3), all three patients treated experienced DLT
(grade 3 fatigue, grade 3 urticaria and grade 3 cardiomyopathy). A
lower dose level of 40mg QD was explored, observing grade 2
creatinine elevation in two out of six patients recruited. Therefore,
30mg QD was considered the MTD for S3.
Tolerability profile. Overall, 10 patients (8.1%) discontinued drug
permanently due to drug-related adverse events, mostly in S3, and
21 (17%) patients experienced a grade X3 drug-related event.
Fatigue and gastrointestinal toxicities (nausea, anorexia and
vomiting) were the commonest adverse events and were dis-
tributed evenly among the different drug schedules. Also, fatigue
and diarrhoea were the more common grade X3 AE (Tables 2A
and B)
Disturbances of the renal function were common: creatinine rise
(defined as increase of at least one grade in CTCAE v3) was
observed in 32 patients (26%) primarily in S3 (29%) and in S1
(32%, most of these in the expansion cohort at 120mg).
(Supplementary Table 2) In contrast, creatinine rise was less
common with weekly administration (15%). Renal impairment on
treatment was not associated with baseline creatinine levels of the
patient, neither with the use of non-steroidal anti-inflammatory
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Figure 1. Schema of the trial design and dose levels explored during the dose escalation phase. The numbers on the left of each dose level refer
to the number of patients treated at dose limiting toxicities in each cohort. Three cohorts were selected for further evaluation in non-randomised
expansion cohorts to pursue pharmacodynamics studies in tumour tissue.
Table 1. Baseline characteristics of the trial population
n %
Gender
Male 60 46.9%
Female 68 53.1%
Age
Median (range) 56.5 yo (19–77)
ECOG PS baseline
0 40 31.3%
1 80 62.5%
2 8 6.3%
Prior therapies
Chemotherapy 126 98.4%
Radiotherapy 57 44.5%
Surgery 111 86.7%
Other 21 16.4%
Number prior therapies for metastatic/advanced disease
Median (range) 2 (1–11)
1–2 60 46.9%
3–4 40 31.3%
X5 28 21.9%
Primary tumour type
Colorectal 32 25.0%
Melanoma 13 10.1%
Renal 11 8.6%
Sarcoma 7 5.5%
Cervix 6 4.7%
GIST 6 4.7%
Ovarian 5 3.9%
Non-small cell lung 3 2.3%
Others 45 35.2%
Schedule of administration (n¼123)
S1: QD, days 1–3 QW 56 45.5%
S2: QWK 39 31.7%
S3: QD continuously 28 22.8%
Abbreviations: QD¼once daily from latin quaque die; QWK¼once weekly.
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drugs nor other baseline concomitant medications. Most of the
creatinine elevations were grade 1, appeared during the first course
of treatment and were reversible, but one case of grade 4 renal
failure was observed in a 53-year-old man with metastatic
transitional cell carcinoma of the bladder after 40 days of
treatment (S3–40mg QD). A CT scan demonstrated disease
progression and the patient deteriorated rapidly, deceasing 1 week
later. Postmortem examination demonstrated tumour infiltration
of glomeruli and tumour embolisms in lung, liver and renal
capillary vessels.
Cardiac function was closely monitored during the study. A 19-
year-old female in the S1–10mg cohort previously treated with
doxorubicin for a metastatic osteosarcoma experienced congestive
heart failure after 3 weeks of treatment; her LVEF dropped from 60
to 48% by echocardiogram. Of the 56 patients enrolled in S1, 21
(38%) presented a drop in the LVEF after 3 weeks of treatment, but
only in one of these cases the decrease was415 percentage points.
The incidence of LVEF drop was similar among the S1 expansion
cohorts (6 out of 14 at 90mg; 5 out of 14 at 120mg).
A 67-year-old man in S1–90mg (reduced to 65mg due to
creatinine rise) with liver and peritoneal metastasis from a
gastrointestinal stromal tumour (GIST) suffered a grade 4
myocardial infarction on day 43 of treatment. Last, one patient
enrolled in the S3–50mg cohort developed a reversible stress
cardiomyopathy (Takotsubo cardiomyopathy) (Dote et al, 1991),
which was considered a DLT. On day 15 of treatment, the patient
reported retrosternal pain and dyspnoea; the echocardiogram
detected an area of anterioapical akinesia with basal hypercontrac-
tion and apical ballooning, (LVEF 40%, compared with 65% at
baseline); OSI-027 was discontinued and the patient underwent
coronary catheterisation, revealing stenosis of the ramus inter-
medius coronary artery (80%), right coronary artery (25%), and left
anterior descending coronary artery (30%). Treatment included
antiagregants, bisoprolol, spironolactone, ramipril and atorvasta-
tin. A follow-up echocardiogram 5 days later showed normal-
isation of the LVEF (68%) and resolution of the apical ballooning.
Drug-related grade 3 hyperglycaemia was only observed in one
individual receiving 160mg QD (S1); cutaneous toxicities, mainly
grade 1–2 macular or maculo-papular rash, occurred in 31 (25%)
patients.
A total of eight individuals died during study participation
(including the post-treatment 30 days follow-up). In seven out of
eight cases, the deaths were judged as related to progression of the
underlying cancer. The other case was a patient in S3 (40mg) who
died of a post-surgical complication after discontinuing drug due
to disease progression.
Pharmacokinetics of OSI-027. All 123 patients dosed with OSI-
027 in this study were included in the PK analysis. The
pharmacokinetic profile of OSI-027 is summarised in Figure 2
and Supplementary Table 3. OSI-027 was absorbed rapidly,
achieving peak plasma concentrations within 4 h. The Tmax was
similar across dose groups, suggesting that the rate of absorption of
OSI-027 was independent of dose. The estimate of half-life was
approximately 14 h (range 8–25 h) with minimal accumulation
observed after once daily dosing. Overall, the exposure of OSI-027
was dose proportional and the range of urinary excretion of
unchanged OSI-027 was 1–7%.
Pharmacodynamics in PBMC and tumour tissue. Drug-
mediated inhibition of mTORC1 and mTORC2 signalling by
OSI-027 was assessed by measuring inhibition of their effectors
p4EBP1 (Thr37/46) and pPRAS40 (Thr246), respectively, in
PBMC. In addition, paired tumour biopsies at screening and
during first month of therapy were used to study target
modulation.
Inhibition of p4EBP1 and pPRAS40 in PBMC by OSI-027 was
dose dependent. Over 50% inhibition of p4EBP1 and pPRAS40 4 h
after dosing was almost universal at doses over 30mg. However,
only with doses over 90mg the effect was maintained over 24 h.
When assessing the intermittent schedule (S1), a dose of 90mg
maintained inhibition 450% of p4EBP1 and pPRAS40 during the
3 days on treatment, but after the 4-day break, both markers
generally returned to baseline levels. Notably, the highest dose
tested (160mg) was able to maintain 450% target inhibition
Table 2A. Treatment emergent adverse events reported in at
least 10% of the trial population.
Number of patients, n (%)
S1
(n¼56)
S2
(n¼39)
S3
(n¼28)
Total
(n¼123)
Gastrointestinal disorders
Nausea 38 (67.9) 22 (56.4) 14 (50) 74 (60.2)
Vomiting 24 (42.9) 8 (20.5) 9 (32.1) 41 (33.3)
Constipation 18 (32.1) 6 (15.4) 7 (25) 31 (25.2)
Diarrhoea 13 (23.2) 8 (20.5) 7 (25) 28 (22.8)
Abdominal pain 8 (14.3) 7 (17.9) 6 (21.4) 21 (17.1)
General disorders
Fatigue 41 (73.2) 24 (61.5) 15 (53.6) 80 (65.0)
Anorexia 28 (50.0) 12 (30.8) 10 (35.7) 50 (40.7)
Weight decreased 10 (17.9) 1 (2.6) 6 (21.4) 17 (13.8)
Headache 10 (17.9) 3 (7.7) 5 (17.9) 18 (14.6)
Laboratory findings
Blood creatinine
increased
19 (33.9) 8 (20.5) 8 (28.6) 35 (28.5)
Hypokalaemia 7 (12.5) 1 (2.6) 7 (25.0) 15 (12.2)
Anaemia 10 (17.9) 5 (12.8) 2 (7.1) 17 (13.8)
Musculoskeletal and connective tissue
Back pain 8 (14.3) 7 (17.9) 3 (10.7) 18 (14.6)
Respiratory and thoracic
Dyspnoea 11 (19.6) 5 (12.8) 5 (17.9) 21 (17.1)
Cough 8 (14.3) 5 (12.8) 5 (17.9) 18 (14.6)
Table 2B. List of grade X3 drug-related adverse events, as
per investigator assessment
Number of patients, n (%)
S1
(n¼56)
S2
(n¼39)
S3
(n¼28)
Total
(n¼123)
Patients with any Grade X3
drug-related events
8 (14.3) 5 (12.8) 8 (28.6) 21 (17.1)
Fatigue 4 (7.1) 1 (2.6) 2 (7.1) 6 (4.9)
Diarrhoea 1 (1.8) 1 (2.6) 1 (3.6) 3 (2.4)
Blood CK increased 0 2 (5.1) 0 2 (1.6)
Hypophosphatemia 2 (3.6) 0 0 2 (1.6)
Lipase increased 1 (1.8) 0 1 (3.6) 2 (1.6)
Blood amylase increased 1 (1.8) 0 0 1 (0.8)
Bone pain 1 (1.8) 0 0 1 (0.8)
Maculo-papular erythematous rash 1 (1.8) 0 0 1 (0.8)
Hyperglycaemia 1 (1.8) 0 0 1 (0.8)
Myocardial infarction 1 (1.8) 0 0 1 (0.8)
Nausea 0 0 1 (3.6) 1 (0.8)
Pneumonia 0 1 (2.6) 0 1 (0.8)
Renal failure 0 0 1 (3.6) 1 (0.8)
Stress cardiomyopathy 0 0 1 (3.6) 1 (0.8)
Urticaria 0 0 1 (3.6) 1 (0.8)
Vomiting 0 0 1 (3.6) 1 (0.8)
Abbreviation: CK¼ creatine kinase.
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during the 4-days off treatment in most patients. The once-a-week
administration of OSI-027 (S2) induced the maximum inhibition
of p4EBP1 and pPRAS40 but the effect was not sustained through
next dose. On an average, there was a direct correlation between
plasma concentrations of OSI-027 and the inhibition of p4EBP1 in
PBMC (Figure 3).
In 21 cases, pre- and postdose paired tumour biopsies were
amenable for PD studies. Average reduction in p4EBP1
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Figure 2. Mean (and s.d.) concentration in plasma of OSI-027 after first dose until next dose in each of the three schedules of administration.
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immunohistochemistry (IHC) staining after drug exposure was
22.3% for 90mg—S1, 49.5% for 120mg—S1 and 67.6% for
240mg—S2, as determined by quantification of digital images
and independent confirmation by a pathologist. Similarly,
assessment of pS6 IHC showed that although 90mg only mildly
reduced pS6 expression (average 28.6%), 120mg of OSI-027
achieved stronger target modulation in tumour tissue, (average
75.3% reduction in pS6).
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Figure 3. Pharmacodynamics of OSI-027 and target modulation. (A) Inhibition of pEBP1 (mTORC1 effector, upper panels) and pPRAS40 (mTORC2
effector, lower panels) in PBMC at 4 and 24h after administration of OSI-027 (all schedules). (B) Correlation between plasma concentrations
of OSI-027 and reduction of p4EBP1 in PBMC for all patients and all time points. (C) Expression of p4EBP1 (left panels) and pS6 (right) by IHC in
tumour biopsies; significantly reduced expression is seen in samples taken after 1 week of treatment with 120mg QD 3 days per week of OSI-027
(S1, pictures on the right) compared with the paired baseline sample of the same patient (pictures on the left).
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Preliminary antitumour activity. No complete or partial
responses were observed. Thirty-eight (29.7%) patients had
stable disease at the first follow-up radiological assessment
(8–12 weeks; Supplementary Figure 1). Of these, six patients
remained free of progression for X24 weeks, including three
patients who remained on therapy for 10–12 months: (1) a woman
with metastatic GIST (S1–120mg) who remained on therapy
for 45 weeks with an overall 20% reduction in the sum of her
target lesions diameters; (2) a patient with metastatic colorectal
cancer (S3–10mg) with a 18% reduction in the size of the lesions
who was on treatment for 49 weeks; and (3) a young patient with
metastatic uveal melanoma who was free of progression for
48 weeks (S3–35mg).
DISCUSSION
This report presents results from a multicentre, first-in-man
clinical trial of OSI-027, a selective mTORC1/mTORC2 inhibitor,
designed to overcome the biological limitations of isolated
mTORC1 blockade with rapalogues.
Three different schedules of administration were investigated.
Although the potentially effective dose of 120mg QD 3 consecutive
days per week (S1) did not result in DLT during the first cycle of
treatment, overall it was considered non tolerable as over half of
the patients necessitated a dose reduction, mainly due to creatinine
elevation. For S2 (once a week schedule), dose escalation was
interrupted at 240mg QWK due to the high number of capsules
required. For the continuous daily dosing (S3), renal toxicity was
dose limiting above 30mg QD.
Absorption of OSI-027 was rapid (Tmax within 4 h across dose
levels). A terminal half-life of 14 h was estimated based on the
weekly dose schedule, with a range of half-life for other groups of
8–25 h. Drug exposure was dose-proportional and there was
minimal accumulation after continuous dosing.
Two dose levels, 90mg and 120mg, on S1 and the highest
administered dose in S2 (240mg) were selected for further
evaluation of pharmacodynamics in non-randomised expansion
cohorts. Data from paired tumour biopsies provided evidence of
target inhibition at doses of 120mg; although target modulation in
PBMC was observed at doses beyond 30mg, target inhibition in
tumour was suboptimal with 90mg of OSI-027, suggesting that
distribution of active drug to solid tissues was limited relative to
circulating blood levels.
The S2 schedule led to the greatest level of target engagement
but this was not sustained for the whole weekly treatment
interval. While this would preclude single agent efficacy it may
be feasible for combination strategies, for example with weekly
chemotherapy; acknowledging the risk of increasing renal
toxicity.
The tolerability profile of the compound was distinct from the
classical effects of rapalogues, as rash, hyperglycaemia or mucositis
were infrequent and mild with OSI-027 (Sonis et al, 2010;
De Masson et al, 2011). Liver function disturbances, which have
been reported as dose limiting for other mTORC1/mTORC2
inhibitors were not common (Naing et al, 2012). In contrast, renal
function disturbances represented clearly a major hurdle in this
study. The risk of renal impairment due to affection of glomerular
permeability or acute tubular necrosis with mTOR inhibition have
been described; the exact mechanism has not been fully elucidated
but may be related to the role of mTOR signalling in renal
regeneration after acute damage (Cina` et al, 2012; Lieberthal and
Levine 2012). Prior similar compounds tested in clinical trials have
not identified renal toxicity as dose-limiting toxicity (Naing et al,
2012; Izzedine et al, 2013; Basu et al, 2015); still, two other cases of
acute renal impairment in patients receiving a dual mTORC1/
mTORC2 inhibitor were reported following the same pattern
observed with OSI-207: acute onset within few days of therapy and
rapid normalisation of kidney function after drug discontinuation
(Izzedine et al, 2013). In this study with OSI-027, intermittent
administration of the study drug partially overcame this problem,
although eventually creatinine rises almost invariably appeared at
higher doses. In this trial, renal toxicity did not seem to be
secondary to dehydration or mucositis but a primary drug-related
event. Cardiac events were the other major concern in the study;
although the frequency was low, three patients experienced severe
events. One patient previously treated with doxorubicin developed
a Takotsubo cardiomyopathy, a reversible transient systolic
dysfunction of unclear pathogenesis, previously related to non-
specific forms of stress, including chemotherapies (Dote et al, 1991;
Qasem et al, 2014).
The design of this first-in-man study attempted to optimise the
integration of the safety data, pharmacokinetics and pharmacody-
namics. The concurrent assessment of various administration
schedules, selected based on preclinical data, and the integration of
PK/PD correlations is an increasing feature of phase I trial design
for targeted agents, aiming to optimise drug delivery and inform
subsequent drug combination studies (Molina et al, 2011).
Moreover, acquisition of paired tumour biopsies permitted the
correlation of target modulation in tumour and PBMC: while
PBMC studies provided valuable proof-of-mechanism for OSI-027,
they did not precisely predict the degree of target engagement in
tumour tissue.
In summary, OSI-027 inhibited mTORC1/mTORC2 in a dose-
dependent manner but the doses necessary for significant target
engagement in tumour were above the tolerable doses in this
clinical trial for either continuous daily or three times a week
dosing. Further studies of this compound would be necessary to
establish any role for once weekly dosing as a potential component
of combination strategies, although a revised formulation might be
required. However, these would need to be approached cautiously
because of the potential for major renal toxicity. On the basis of the
PD and tolerability data from this study, further clinical
development of the compound as a single agent has been
discontinued.
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